Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Financing Liver & Hepatic

NorthSea Raises Cash For NASH Program

Executive Summary

NorthSea raises €25m to push icosabutate, its only clinical compound, which was licensed from Pronova BioPharma, into Phase IIb trials for fatty liver disease. The drug has previously been tested in hypertriglyceridemia and dyslipidemia.

You may also be interested in...



Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans. 

New Cash Moves NorthSea Up In NASH

With two new US investors on board, NST is financed to complete a Phase IIb trial of icosabutate in non-alcoholic steatohepatitis.

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

Table

View full table

Topics

Related Companies

Tags:
Business Strategies Financing Liver & Hepatic
Latest Headlines

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

See All
UsernamePublicRestriction

Register

SC100039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By